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Summary
Background The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-
positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the 
SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen 
fulvestrant in combination with continued oestrogen deprivation.
Methods In a composite, multicentre, phase 3 randomised controlled trial done in the UK and South Korea, 
postmenopausal women with hormone-receptor-positive breast cancer (oestrogen receptor [ER] positive, progesterone 
receptor [PR] positive, or both) were eligible if they had relapsed or progressed with locally advanced or metastatic 
disease on an NSAI (given as adjuvant for at least 12 months or as ﬁ rst-line treatment for at least 6 months). 
Additionally, patients had to have adequate organ function and a WHO performance status of 0–2. Participants were 
randomly assigned (1:1:1) to receive fulvestrant (500 mg intramuscular injection on day 1, followed by 250 mg doses 
on days 15 and 29, and then every 28 days) plus daily oral anastrozole (1 mg); fulvestrant plus anastrozole-matched 
placebo; or daily oral exemestane (25 mg). Randomisation was done with computer-generated permuted blocks, and 
stratiﬁ cation was by centre and previous use of an NSAI as adjuvant treatment or for locally advanced or metastatic 
disease. Participants and investigators were aware of assignment to fulvestrant or exemestane, but not of assignment 
to anastrozole or placebo. The primary endpoint was progression-free survival (PFS). Analyses were by intention to 
treat. This trial is registered with ClinicalTrials.gov, numbers NCT00253422 (UK) and NCT00944918 (South Korea).
Findings Between March 26, 2004, and Aug 6, 2010, 723 patients underwent randomisation: 243 were assigned to 
receive fulvestrant plus anastrozole, 231 to fulvestrant plus placebo, and 249 to exemestane. Median PFS was 
4·4 months (95% CI 3·4–5·4) in patients assigned to fulvestrant plus anastrozole, 4·8 months (3·6–5·5) in those 
assigned to fulvestrant plus placebo, and 3·4 months (3·0–4·6) in those assigned to exemestane. No diﬀ erence was 
recorded between the patients assigned to fulvestrant plus anastrozole and fulvestrant plus placebo (hazard ratio 
1·00, 95% CI 0·83–1·21; log-rank p=0·98), or between those assigned to fulvestrant plus placebo and exemestane 
(0·95, 0·79–1·14; log-rank p=0·56). 87 serious adverse events were reported: 36 in patients assigned to fulvestrant 
plus anastrozole, 22 in those assigned to fulvestrant plus placebo, and 29 in those assigned to exemestane. Grade 3–4 
adverse events were rare; the most frequent were arthralgia (three in the group assigned to fulvestrant plus anastrozole; 
seven in that assigned to fulvestrant plus placebo; eight in that assigned to exemestane), lethargy (three; 11; 11), and 
nausea or vomiting (ﬁ ve; two; eight).
Interpretation After loss of response to NSAIs in postmenopausal women with hormone-receptor-positive advanced 
breast cancer, maximum double endocrine treatment with 250 mg fulvestrant combined with oestrogen deprivation 
is no better than either fulvestrant alone or exemestane.
Funding Cancer Research UK and AstraZeneca.
Introduction
The optimum endocrine treatment for postmenopausal 
women with advanced hormone-receptor-positive breast 
cancer that has progressed during treatment with non-
steroidal aromatase inhibitors (NSAIs) is unclear.1 The 
steroidal aromatase inactivator exemestane2,3 and the 
steroidal oestrogen-receptor downregulator fulvestrant4,5 
have been recognised standards of care in this setting. 
The phase 3 EFECT trial6 showed no diﬀ erence in clinical 
eﬃ  cacy between these two treatments for patients with 
oestrogen receptor (ER)-positive metastatic breast cancer 
in the ﬁ rst-line and second-line settings.
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Treatment options in the setting of acquired 
resistance to NSAIs in ER-positive advanced breast 
cancer have changed since the results of the BOLERO-2 
trial were reported.7,8 This trial showed that progression-
free survival (PFS) was longer with the combination of 
exemestane and the mTOR antagonist everolimus than 
with exemestane alone.8 However, whether double 
endocrine targeting would be more eﬀ ective than a 
partially non-cross-resistant endocrine agent in the 
setting of acquired resistance is unclear. Preclinical 
studies9,10 have suggested that the eﬃ  cacy of 
fulvestrant could be increased in a low oestrogen 
environment. As a competitive antagonist for ER, 
oestradiol can compete with fulvestrant for receptor-
site occupancy. In MCF-7 aromatase-transfected 
xenografts, the combination of fulvestrant and an 
aromatase inhibitor was more eﬀ ective than either 
treatment alone.11,12 Furthermore, in model systems of 
acquired resistance to long-term oestrogen deprivation, 
breast cancer cells seem to be stimulated by low 
residual amounts of oestrogens, which potentially 
could be enhanced on withdrawal of oestrogen 
suppression at the time of progression.13,14
Thus, a maximum double endocrine targeting 
approach in the setting of acquired resistance to NSAIs 
should be investigated with fulvestrant in combination 
with continued oestrogen deprivation. The Study of 
Faslodex with or without concomitant Arimidex vs 
Exemestane following progression on non-steroidal 
Aromatase inhibitors (SoFEA) was designed. 
Exemestane was the appropriate standard of care 
(control) at the time the trial was designed and was 
compared with the then accepted optimum dosing 
schedule for fulvestrant.
Methods
Study design and participants
SoFEA was a phase 3 multicentre randomised controlled 
trial that was done in 82 UK centres. Additionally, 
investigators in South Korea expressed interest in joining 
the trial. To simplify governance arrangements, a parallel 
trial, sponsored by AstraZeneca and following the SoFEA 
protocol and case report forms, was initiated. Patients 
were recruited from four South Korean centres. The 
SoFEA trial as presented here represents a composite of 
the UK and South Korean initiatives.
Postmenopausal women with hormone-receptor-
positive breast cancer (ER positive or progesterone 
receptor [PR] positive, or both) were eligible if they 
relapsed or progressed with locally advanced or 
metastatic disease on an NSAI. The NSAI had to have 
been given as adjuvant treatment for at least 12 months, 
or as ﬁ rst-line treatment for locally advanced or 
metastatic disease for at least 6 months. Patients had to 
have adequate haematological, hepatic, and renal 
function, and a WHO performance status of 0–2. 
Patients already established on bisphosphonate 
treatment for at least 6 months or those who were due 
to start bisphosphonate treatment for bone metastases 
with other assessable sites of disease were eligible. 
Patients could have previously received tamoxifen and 
chemotherapy in the adjuvant or neoadjuvant setting or 
chemotherapy as ﬁ rst-line treatment for metastatic 
breast cancer followed by an NSAI alone for at least 
6 months. Patients were excluded if they had rapidly 
progressing visceral disease, malignancies other than 
breast cancer in the previous 5 years (except for 
adequately treated in-situ carcinoma of the cervix, or 
basal-cell or squamous-cell carcinoma of the skin), or 
thrombocytopenia (because of the risk of bleeding with 
intramuscular injection of fulvestrant). Additionally, 
patients who had received systemic corticosteroids for 
more than 15 days in the 4 weeks before randomisation 
were excluded.
In the UK, this trial was approved by the Medicines and 
Healthcare products Regulatory Authority and 
South West 2 Multi-Research Ethics Committee (MREC 
03/6/77). In South Korea, the study was approved by 
Korea Food and Drug Administration and local 
institutional review boards. All patients provided written 
informed consent. The Institute of Cancer Research-
Clinical Trials and Statistics Unit (ICR-CTSU; London, 
UK) had overall responsibility for trial management; two 
additional collaborating trials units, Cancer Clinical 
Trials Team Information Services Division (Edinburgh, 
UK) and C+R Research (Seoul, South Korea), were 
responsible for regional data management. The trial 
management group was responsible for day-to-day 
running of the trial. The trial was overseen by an 
independent trial steering committee. Emerging safety 
and eﬃ  cacy data were conﬁ dentially reviewed regularly 
by the independent data monitoring committee.Figure 1: Trial proﬁ le
723 patients randomly assigned
231 assigned to fulvestrant 
plus placebo
243 assigned to fulvestrant 
plus anastrozole
249 assigned to exemestane
230 received assigned 
treatment
241 received assigned 
treatment
2 did not start treatment 1 did not start treatment 2 did not start treatment
238 discontinued
 221 progressed
 3 died
 7 had adverse events
 7 decision by patient 
  or investigator
222 discontinued
 207 progressed
 8 had adverse events
 7 decision by patient 
  or investigator
237 discontinued
 213 progressed
 6 died
 9 had adverse events
 9 decision by patient 
  or investigator
247 received assigned 
treatment
8 still on treatment3 still on treatment 10 still on treatment
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Randomisation and masking
Patients were randomly assigned (1:1:1) to receive 
fulvestrant plus anastrozole, fulvestrant plus placebo, or 
exemestane. Computer-generated permuted blocks were 
used, and stratiﬁ cation was by centre and previous use of 
an NSAI as adjuvant treatment or for locally advanced or 
metastatic disease. Independent randomisation was by 
telephone to ICR-CTSU and the Information Services 
Division in the UK and AstraZeneca in South Korea. 
Participants and investigators were aware of assignment 
to fulvestrant or exemestane, but not of assignment to 
anastrozole or placebo for patients in the groups assigned 
to fulvestrant.
Procedures
Fulvestrant was given with a loading dose schedule of a 
500 mg intramuscular injection into the gluteus 
maximus on day 1, followed by 250 mg injections on 
days 15 and 29. Thereafter, 250 mg intramuscular 
injections were done every 28 days. Injections were given 
slowly, over the course of at least 2 min. Anastrozole 
(1 mg), matched placebo, and exemestane (25 mg) were 
given orally once daily. All treatments were given until 
disease progression or withdrawal.
Data for treatment compliance were obtained for 
fulvestrant only, for which a delay was allowed for 
recovery from toxic eﬀ ects. Dose reductions are not 
standard for the treatments investigated in this trial. 
Timing of and reasons for treatment discontinuation 
were recorded. Fulvestrant, anastrozole, and the 
anastrozole-matched placebo were supplied by 
AstraZeneca. Exemestane was dispensed from hospital 
pharmacies or via the patient’s primary-care physician.
Clinical assessment and toxicity reporting occurred 
monthly during the ﬁ rst 6 months, and every 3 months 
thereafter while treatment continued. Tumour assessment 
with Response Evaluation Criteria in Solid Tumors 
(RECIST; version 1.0) was done every 3 months and at 
discontinuation or withdrawal from treatment. Adverse 
events were graded according to National Cancer Institute 
Common Toxicity Criteria (version 3.0) and coded with the 
Medical Dictionary for Regulatory Activities (MedDRA; 
version 14.0), with central clinical review by SRDJ.
The primary endpoint was PFS, which was deﬁ ned as 
time from randomisation to progression of existing 
disease, new sites of disease, second primary cancer if 
change in systemic treatment was necessary, or death 
from any cause. Secondary endpoints were overall 
survival (time from randomisation to death from any 
cause), objective response (proportion achieving 
complete or partial response on trial treatment), clinical 
beneﬁ t (proportion achieving complete or partial 
response, or stable disease for at least 6 months on trial 
treatment), duration of response or clinical beneﬁ t (PFS 
in patients who had an objective response or clinical 
beneﬁ t), time to treatment failure (not reported here), 
and tolerability and safety.
Plasma oestradiol concentrations at baseline and 
3 months were also measured as an exploratory endpoint 
in a subset of patients who underwent randomisation 
after Nov 19, 2007, and who consented to and contributed 
at least one blood sample. Oestradiol analyses were done 
by Pharmanet (Princeton, NJ, USA) by gas chromatography 
tandem mass spectrometry with negative ion chemical 
ionisation after derivatisation of the steroid. The sensitivity 
of the assay was 0·625 pg/mL (2·3 pmol/L).
Statistical analysis
The sample size was based on two primary aims: to detect 
an improvement in median PFS from 5·5 to 7·5 months 
in patients allocated to fulvestrant plus anastrozole 
compared with fulvestrant plus placebo, and from 
4·0 to 5·5 months in patients allocated to fulvestrant 
compared with exemestane. With a minimum follow-up 
of 6 months, 5% signiﬁ cance level (two-sided), and 90% 
power, 750 patients (250 per group) with 440 progression 
Fulvestrant plus 
anastrozole (n=243)
Fulvestrant plus 
placebo (n=231)
Exemestane 
(n=249)
Age at randomisation (years) 63·8 (57·0–72·0) 63·4 (57·0–73·5) 66·0 (59·2–75·0)
Hormone-receptor status
ER positive, PR positive 120 (49%) 124 (54%) 132 (53%)
ER positive, PR negative 38 (16%) 33 (14%) 23 (9%)
ER positive, PR unknown 83 (34%) 71 (31%) 91 (37%)
ER negative or unknown, PR positive 2 (1%) 1 (<1%) 2 (1%)
ER unknown, PR unknown 0 2 (1%) 1 (<1%)
HER2 status
Positive 17 (7%) 14 (6%) 17 (7%)
Negative 122 (50%) 141 (61%) 142 (57%)
Unknown 104 (43%) 76 (33%) 90 (36%)
Previous tamoxifen in adjuvant setting 171 (70%) 170 (74%) 166 (67%)
Time from primary diagnosis to ﬁ rst 
relapse (years)
5·0 (2·3–10·0) 5·1 (2·4–9·7) 5·2 (2·0–10·2)
Time on NSAI before randomisation 
(months)
21·5 (13·4–34·0) 21·2 (12·0–34·5) 20·1 (12·9–32·9)
Adjuvant 35·0 (24·0–44·7) 24·9 (17·4–41·9) 24·2 (18·5–41·9)
Locally advanced or metastatic breast 
cancer
20·1 (12·6–29·2) 18·6 (11·7–33·1) 19·3 (12·1–31·0)
NSAI setting and time on NSAI
Adjuvant 42 (17%) 50 (22%) 42 (17%)
Locally advanced or metastatic breast 
cancer; <1 year
44 (18%) 49 (21%) 51 (20%)
Locally advanced or metastatic breast 
cancer; 1 to <2 years
87 (36%) 61 (26%) 88 (35%)
Locally advanced or metastatic breast 
cancer; ≥2 years
70 (29%) 71 (31%) 68 (27%)
Site of relapse*
Visceral 138 (57%) 143 (62%) 145 (58%)
Soft tissue or node 68 (28%) 50 (22%) 71 (29%)
Bone 37 (15%) 37 (16%) 32 (13%)
Data are n (%) or median (IQR). ER=oestrogen receptor. PR=progesterone receptor. NSAI=non-steroidal aromatase 
inhibitor. *Data missing for one patient assigned to fulvestrant plus placebo and one assigned to exemestane.
Table 1: Baseline characteristics
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events in the two fulvestrant groups were needed for the 
principal analysis. Because of a long period of recruitment, 
in 2010, the independent data monitoring committee 
agreed that the data were suﬃ  ciently mature for 
723 enrolled patients to answer the principal questions 
with the same number of events, but in a smaller total 
number of patients who had been followed up for a longer 
period than originally anticipated.
The principal eﬃ  cacy analyses included all patients who 
underwent randomisation on an intention-to-treat basis. 
Survival endpoints were shown graphically with Kaplan-
Meier plots, and treatment comparisons made with the 
log-rank test. Hazard ratios (HRs) were obtained from Cox 
proportional hazards regression models, with HRs of less 
than 1 favouring fulvestrant plus anastrozole in the 
comparison of fulvestrant plus placebo and fulvestrant 
plus anastrozole, and fulvestrant plus placebo in the 
comparison of fulvestrant plus placebo and exemestane. 
The proportionality assumption of the Cox model was 
tested with Schoenfeld residuals, and was shown to hold.
Subgroup analyses were reported with forest plots for 
age at randomisation, ER and PR status, HER2 status, 
time from diagnosis to ﬁ rst relapse, dominant site of 
relapse, and NSAI setting and time on NSAI combined. 
In view of the absence of standard prognostic factors in 
this setting, and to avoid overparameterisation of a 
multivariable model, baseline characteristics were 
assessed for prognostic ability, irrespective of treatment 
eﬀ ect. Variables shown to be signiﬁ cant were combined 
in a multivariable model with a forward stepwise method. 
Treatment was then added to the model to obtain the 
adjusted HR for treatment eﬀ ect. Proportions of 
responses were compared with Fisher’s exact tests.
Safety analyses were done for all patients who received at 
least one dose of trial treatment (as treated population). 
The worst grade of adverse event during trial treatment 
was reported and compared with Fisher’s exact tests. 
All prespeciﬁ ed toxic eﬀ ects and any MedDRA-coded event 
satisfying predeﬁ ned criteria (ie, ≥10% frequency, p<0·01, 
or >1% diﬀ erence in frequency between treatment groups) 
are presented. A signiﬁ cance level of <0·01 allowed some 
adjustment for multiple testing of toxicity endpoints. 
Geometric mean oestradiol concentrations were calculated 
by treatment group at each timepoint.
This analysis includes all data received and processed 
by Jan 3, 2012. Data were collated at ICR-CTSU, where all 
interim and ﬁ nal analyses were done. Central statistical 
monitoring was done by ICR-CTSU and was supple-
mented by selected on-site source document veriﬁ cation. 
All analyses were done in Stata (version 10.1).
This trial is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN44195747, 
and with ClinicalTrials.gov, numbers NCT00253422 (UK) 
and NCT00944918 (South Korea).
Role of the funding source
The trial was cosponsored by The Royal Marsden NHS 
Foundation Trust and The Institute of Cancer Research in 
the UK; AstraZeneca sponsored the trial in South Korea. 
The funders had no role in data collection, data analysis, 
data interpretation, or writing of the report. The study 
design was peer-reviewed by Cancer Research UK and the 
protocol was approved by the trial sponsors and 
AstraZeneca. SRDJ, LSK, and JMB had full access to all 
the data in the study, and SRDJ had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between March 26, 2004, and Aug 6, 2010, 723 patients 
underwent randomisation (ﬁ gure 1): 698 from the UK 
Figure 2: Progression-free survival
(A) Fulvestrant plus anastrozole vs fulvestrant plus placebo. (B) Fulvestrant plus placebo vs exemestane. 
HR=hazard ratio.
Fulvestrant plus anastrozole (median 4·4 months, 95% CI 3·4–5·4) 
Fulvestrant plus placebo (median 4·8 months, 95% CI 3·6–5·5)
Fulvestrant plus placebo (median 4·8 months, 95% CI 3·6–5·5)
Exemestane (median 3·4 months, 95% CI 3·0–4·6)
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and 25 from South Korea. Baseline characteristics, such 
as time from diagnosis to ﬁ rst relapse and sites of 
dominant disease, are representative of a population of 
patients with hormone-receptor-positive metastatic 
breast cancer (table 1). 589 (81%) had previously received 
an NSAI in the locally advanced or metastatic setting for 
a median of 19·3 months (IQR 12·1–31·2; table 1), 
suggesting that this population had a good response to 
previous NSAI treatment. Four patients assigned to 
fulvestrant plus anastrozole missed a fulvestrant 
injection, and 109 patients (50 assigned to fulvestrant 
plus anastrozole; 59 assigned to fulvestrant plus placebo) 
had at least one scheduled fulvestrant dose delay.
After a median follow-up in all patients of 37·9 months 
(IQR 23·1–50·8), 689 progression events were reported: 
235 in patients assigned to fulvestrant plus anastrozole, 
221 in those assigned to fulvestrant plus placebo, and 233 
in those assigned to exemestane. No diﬀ erence in PFS 
was recorded between patients assigned to fulvestrant 
plus anastrozole and fulvestrant plus placebo, or between 
those assigned to fulvestrant plus placebo and exemestane 
(ﬁ gure 2). A multivariable analysis with adjustment for 
time from diagnosis to ﬁ rst relapse, number of disease 
sites present at baseline, and NSAI setting and time on 
NSAI did not substantially aﬀ ect estimates of treatment 
eﬀ ect (fulvestrant plus anastrozole vs fulvestrant plus 
placebo: HR 1·05, 95% CI 0·87–1·26, p=0·62; fulvestrant 
plus placebo vs exemestane: 0·92, 0·77–1·11, p=0·41). 
Subgroup analyses were consistent with the overall eﬀ ect 
on PFS (ﬁ gure 3).
508 patients had died: 168 (69%) assigned to fulvestrant 
plus anastrozole, 167 (72%) to fulvestrant plus placebo, 
Figure 3: Subgroup analyses of progression-free survival
(A) Fulvestrant plus anastrozole vs fulvestrant plus placebo. (B) Fulvestrant plus placebo vs exemestane. ER=oestrogen receptor. PR=progesterone receptor. NSAI=non-steroidal aromatase inhibitor. 
*Data for the few patients with ER-negative or unknown, and PR-positive disease, and those with unknown hormone-receptor-status not shown here. †Data missing for one patient assigned to 
fulvestrant plus placebo and one assigned to exemestane. ‡Adjusted for time from diagnosis to ﬁ rst relapse, number of disease sites at baseline, and NSAI setting and time on NSAI.
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HER2 negative 263
HER2 positive 31
HER2 unknown 180
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≥5 241
Dominant site of relapse†
Visceral  281
Soft tissue or node 118
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   <1 year 93
   1 to <2 years  148
   ≥2 141
Country
UK 459
South Korea 15
Overall 474‡
 27
 210
 135
 108
 256
 56
 162
 283
 31
 166
 79
 75
 82
 244
 288
 121
 69
 92
 100
 149
 139
 465
 15
 480‡
0·90 (0·49–1·67)
0·92 (0·70–1·21)
1·01 (0·70–1·44)
1·06 (0·69–1·63)
0·85 (0·66–1·10)
1·30 (0·80–2·10)
1·17 (0·84–1·63)
0·95 (0·75–1·22)
1·44 (0·68–3·05)
1·03 (0·76–1·40)
0·90 (0·56–1·46)
1·34 (0·84–2·15)
0·89 (0·58–1·37)
1·06 (0·82–1·38)
1·10 (0·86–1·39)
0·98 (0·67–1·43)
0·99 (0·61–1·59)
0·97 (0·64–1·47)
0·95 (0·63–1·44)
1·26 (0·90–1·77)
0·85 (0·60–1·19)
1·00 (0·83–1·20)
1·74 (0·46–6·62)
1·05 (0·87–1·26)
1·51 (0·59–3·85)
0·94 (0·72–1·25)
0·81 (0·57–1·15)
0·95 (0·64–1·42)
0·94 (0·71–1·23)
0·85 (0·49–1·48)
0·93 (0·67–1·29)
1·06 (0·83–1·34)
0·20 (0·08–0·51)
0·93 (0·68–1·27)
1·18 (0·74–1·89)
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0·90 (0·59–1·38)
1·27 (0·84–1·91)
0·75 (0·54–1·06)
1·06 (0·75–1·50)
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and 173 (69%) to exemestane. Most deaths were due to 
breast cancer. Only 12 deaths were reportedly due to 
other causes: cardiovascular (one patient assigned to 
fulvestrant plus anastrozole, two to fulvestrant plus 
placebo), cerebrovascular (one assigned to fulvestrant 
plus placebo, one to exemestane), primary lung cancer 
(one assigned to fulvestrant plus placebo, one to 
exemestane), pneumonia (one assigned to fulvestrant 
plus anastrozole, one to exemestane), neutropenic sepsis 
(one assigned to fulvestrant plus placebo), and unknown 
(one assigned to fulvestrant plus anastrozole, one to 
exemestane). Only two of the deaths due to causes other 
than breast cancer (one pneumonia and one unknown) 
occurred on trial treatment, and neither was deemed to 
be related to treatment.
No diﬀ erence in overall survival was recorded between 
patients assigned to fulvestrant plus anastrozole and 
fulvestrant plus placebo, or between those assigned to 
fulvestrant plus placebo and exemestane (ﬁ gure 4). 
Subgroup analyses were consistent with the overall eﬀ ect 
on overall survival (appendix).
In the intention-to-treat population, 18 (7%) of 
243 patients assigned to fulvestrant plus anastrozole 
had objective tumour responses (one complete 
response, 17 partial response), as did 16 (7%) of 
231 assigned to fulvestrant plus placebo (all partial 
response), and nine (4%) of 249 assigned to exemestane 
(two complete response, seven partial response; 
fulvestrant plus anastrozole vs fulvestrant plus placebo: 
p=0·88; fulvestrant plus placebo vs exemestane: 
p=0·27). 558 patients (77%) had measurable disease: 
194 (80%) assigned to fulvestrant plus anastrozole, 
178 (77%) to fulvestrant plus placebo, and 186 (75%) to 
exemestane. Of these patients, 15 (8%) patients 
assigned to fulvestrant plus anastrozole achieved 
objective responses (all partial response), as did 14 (8%) 
assigned to fulvestrant plus placebo (all partial 
response), and seven (4%) assigned to exemestane (one 
complete response, six partial response; fulvestrant 
plus anastrozole vs fulvestrant plus placebo: p=1·00; 
fulvestrant plus placebo vs exemestane: p=0·17). 
Median duration of objective response was 12·3 months 
(IQR 5·7–22·1) for patients assigned to fulvestrant plus 
anastrozole, 16·5 months (7·8–29·2) for those assigned 
to fulvestrant plus placebo, and 17·2 months (9·6–26·9) 
for those assigned to exemestane.
82 patients (34%) assigned to fulvestrant plus 
anastrozole, 73 (32%) assigned to fulvestrant plus 
placebo, and 67 (27%) assigned to exemestane achieved 
clinical beneﬁ t (fulvestrant plus anastrozole vs fulvestrant 
plus placebo: p=0·75; fulvestrant plus placebo vs 
exemestane: p=0·27). In patients with measurable 
disease, 63 (33%) assigned to fulvestrant plus anastrozole, 
55 (31%) assigned to fulvestrant plus placebo, and 43 
(23%) assigned to exemestane achieved clinical beneﬁ t 
(fulvestrant plus anastrozole vs fulvestrant plus placebo: 
p=0·94; fulvestrant plus placebo vs exemestane: p=0·16). 
Median duration of clinical beneﬁ t was 13·0 months 
(8·9–18·9) for patients assigned to fulvestrant plus 
anastrozole, 13·0 months (8·3–17·5) for those assigned 
to fulvestrant plus placebo, and 13·0 months (9·3–21·7) 
for those assigned to exemestane.
87 serious adverse events were reported, of which 
three were suspected unexpected serious adverse 
reactions (one in the group assigned to fulvestrant plus 
anastrozole and two in the group assigned to fulvestrant 
plus placebo) and 11 were serious adverse reactions 
(six in the group assigned to fulvestrant plus anastrozole, 
three in that assigned to fulvestrant plus placebo, and 
Figure 4: Overall survival
(A) Fulvestrant plus anastrozole vs fulvestrant plus placebo. (B) Fulvestrant plus placebo vs exemestane. 
HR=hazard ratio.
Fulvestrant plus anastrozole (median 20·2 months, 95% CI 17·2–22·5)
Fulvestrant plus placebo (median 19·4 months, 95% CI 16·8–22·8)
Fulvestrant plus placebo (median 19·4 months, 95% CI 16·8–22·8)
Exemestane (median 21·6 months, 95% CI 19·4–23·9)
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Fulvestrant plus anastrozole 
(n=241)
Fulvestrant plus placebo 
(n=230)
Exemestane (n=247) p value fulvestrant plus 
anastrozole vs 
fulvestrant plus placebo
p value fulvestrant 
plus placebo vs 
exemestane
Any grade Grades 3 and 4 Any grade Grades 3 and 4 Any grade Grades 3 and 4
Upper abdominal pain 3 (1%) 0 1 (<1%) 0 5 (2%) 1 (<1%) 0·62 0·22
Alopecia* 25 (10%) 0 31 (13%) 0 32 (13%) 0 0·32 0·89
Anaemia 5 (2%) 0 3 (1%) 1 (<1%) 6 (2%) 2 (1%) 0·73 0·51
Arthralgia* 97 (40%) 3 (1%) 98 (43%) 7 (3%) 115 (47%) 8 (3%) 0·64 0·41
Back pain 18 (7%) 1 (<1%) 23 (10%) 0 18 (7%) 1 (<1%) 0·41 0·33
Bone pain 21 (9%) 3 (1%) 13 (6%) 3 (1%) 17 (7%) 3 (1%) 0·22 0·71
Breast pain 5 (2%) 1 (<1%) 3 (1%) 0 7 (3%) 0 0·73 0·34
Cellulitis 4 (2%) 1 (<1%) 1 (<1%) 0 1 (<1%) 0 0·37 1·00
Chest pain 6 (2%) 1 (<1%) 8 (3%) 4 (2%) 11 (4%) 0 0·60 0·65
Constipation* 64 (27%) 2 (1%) 57 (25%) 0 58 (23%) 1 (<1%) 0·67 0·75
Cough 8 (3%) 0 20 (9%) 1 (<1%) 17 (7%) 0 0·02 0·50
Decreased appetite* 73 (30%) 1 (<1%) 63 (27%) 3 (1%) 70 (28%) 3 (1%) 0·54 0·84
Diarrhoea* 40 (17%) 1 (<1%) 53 (23%) 2 (1%) 47 (19%) 0 0·08 0·31
Dizziness 12 (5%) 0 9 (4%) 0 16 (6%) 0 0·66 0·23
Dry skin 0 0 6 (3%) 0 3 (1%) 0 0·01 0·32
Dysgeusia 2 (1%) 0 4 (2%) 0 1 (<1%) 0 0·44 0·20
Dyspepsia* 52 (22%) 0 59 (26%) 1 (<1%) 72 (29%) 0 0·33 0·41
Dysphagia 0 0 3 (1%) 0 1 (<1%) 0 0·12 0·36
Dysphonia 0 0 3 (1%) 0 2 (1%) 0 0·12 0·68
Dyspnoea 17 (7%) 1 (<1%) 35 (15%) 5 (2%) 26 (11%) 2 (1%) 0·005 0·13
Fatigue 7 (3%) 1 (<1%) 8 (3%) 2 (1%) 11 (4%) 0 0·80 0·65
Headache* 49 (20%) 1 (<1%) 64 (28%) 2 (1%) 52 (21%) 1 (<1%) 0·07 0·09
Hot ﬂ ush* 88 (37%) 2 (1%) 81 (35%) 5 (2%) 83 (34%) 1 (<1%) 0·77 0·77
Hyperhidrosis 4 (2%) 0 1 (<1%) 0 1 (<1%) 0 0·37 1·00
Hypertension 4 (2%) 2 (1%) 3 (1%) 1 (<1%) 0 0 1·00 0·11
Hypotension 0 0 3 (1%) 0 1 (<1%) 1 (<1%) 0·12 0·36
Infection 1 (<1%) 0 1 (<1%) 0 8 (3%) 0 1·00 0·04
Insomnia* 75 (31%) 1 (<1%) 63 (27%) 5 (2%) 72 (29%) 3 (1%) 0·42 0·69
Joint swelling 3 (1%) 0 4 (2%) 0 1 (<1%) 0 0·72 0·20
Lethargy* 151 (63%) 3 (1%) 144 (63%) 11 (5%) 134 (54%) 11 (5%) 1·00 0·08
Localised infection 1 (<1%) 0 1 (<1%) 0 4 (2%) 0 1·00 0·37
Lower-respiratory-tract infection 17 (7%) 2 (1%) 15 (7%) 0 13 (5%) 2 (1%) 0·86 0·57
Lymphoedema 6 (2%) 0 2 (1%) 0 4 (2%) 0 0·29 0·69
Altered mood* 53 (22%) 0 56 (24%) 3 (1%) 60 (24%) 1 (<1%) 0·59 1·00
Mucosal inﬂ ammation* 15 (6%) 0 22 (10%) 0 15 (6%) 0 0·23 0·17
Muscular weakness 3 (1%) 0 0 0 2 (1%) 0 0·25 0·50
Musculoskeletal chest pain 8 (3%) 0 7 (3%) 0 5 (2%) 1 (<1%) 1·00 0·57
Musculoskeletal pain 11 (5%) 0 6 (3%) 1 (<1%) 6 (2%) 1 (<1%) 0·33 1·00
Myalgia 10 (4%) 0 5 (2%) 1 (<1%) 5 (2%) 0 0·30 1·00
Nausea or vomiting* 83 (34%) 5 (2%) 100 (43%) 2 (1%) 92 (37%) 8 (3%) 0·05 0·19
Neck pain 2 (1%) 2 (1%) 1 (<1%) 0 4 (2%) 0 1·00 0·37
Peripheral neuropathy 1 (<1%) 0 6 (3%) 1 (<1%) 5 (2%) 0 0·06 0·77
Peripheral oedema 8 (3%) 0 3 (1%) 0 6 (2%) 0 0·22 0·51
Oral candidosis 0 0 3 (1%) 0 0 0 0·12 0·11
Oropharyngeal pain 3 (1%) 0 4 (2%) 0 0 0 0·72 0·05
Pain 4 (2%) 0 15 (7%) 3 (1%) 10 (4%) 2 (1%) 0·009 0·30
Pain in extremity 15 (6%) 0 6 (3%) 0 13 (5%) 0 0·07 0·16
Paraesthesia 4 (2%) 0 1 (<1%) 0 3 (1%) 0 0·37 0·62
Pruritus 4 (2%) 0 3 (1%) 0 6 (2%) 0 1·00 0·51
(Continues on next page)
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two in that assigned to exemestane). Of the other 
73 serious adverse events, 29 were in the group assigned 
to fulvestrant plus anastrozole, 17 in that assigned 
to fulvestrant plus placebo, and 27 in that assigned to 
exemestane. Frequency of dyspnoea and pain (any grade) 
was higher in patients assigned to fulvestrant plus 
placebo than in those assigned to fulvestrant plus 
anastrozole; no other diﬀ erences between groups were 
noted (table 2). Grade 3 and 4 adverse events were rare; 
the most frequent were arthralgia, lethargy, and nausea 
or vomiting (table 2).
Oestradiol concentrations in 94 (26%) of 363 patients 
who underwent randomisation after Nov 19, 2007, 
showed that oestrogen continued to be suppressed at 
3 months in patients assigned to fulvestrant plus 
anastrozole and exemestane, but not in those assigned to 
fulvestrant plus placebo (ﬁ gure 5).
Discussion
Our study shows no beneﬁ t for the combination of 
fulvestrant and anastrozole in the setting of acquired 
endocrine resistance in hormone-receptor-positive breast 
cancer compared with fulvestrant alone. Likewise, no 
signiﬁ cant diﬀ erence was reported between fulvestrant 
alone and exemestane, conﬁ rming the results of EFECT6 
(panel). These results provide clear evidence that 
endocrine treatment after loss of response to NSAIs in 
hormone-receptor-positive advanced breast cancer has 
little eﬃ  cacy, with a median PFS of only about 
3–4 months. So, does combined maximum endocrine 
treatment have any role as a treatment option for 
hormone-receptor-positive advanced breast cancer?
SoFEA diﬀ ered from two other trials of fulvestrant 
(250 mg) plus anastrozole in the ﬁ rst-line setting,15,16 in 
terms of the comparator and the patients studied 
(second-line with acquired endocrine resistance). In the 
FACT study,15 no diﬀ erence was reported for time to 
disease progression between fulvestrant plus 
anastrozole and anastrozole alone. However, in the 
SWOG 0226 study,16 a signiﬁ cant diﬀ erence between 
these regimens was reported in both PFS and overall 
survival, although the beneﬁ t seemed to be restricted to 
the 60% of study patients who had received no previous 
adjuvant endocrine treatment. Thus, although 
fulvestrant combined with an aromatase inhibitor 
might be no better than either fulvestrant or exemestane 
alone in the second-line endocrine resistant setting, 
dual endocrine targeting could still be beneﬁ cial in the 
true ﬁ rst-line hormone-sensitive setting. In preclinical 
models of hormone-sensitive breast cancer,11,12 the 
combination of fulvestrant plus anastrozole produced 
the greatest tumour inhibition compared with either 
drug alone. Notably in our study, patients with known 
ER-positive and PR-positive tumours seemed to show 
the greatest beneﬁ t for fulvestrant plus anastrozole, 
Fulvestrant plus anastrozole 
(n=241)
Fulvestrant plus placebo 
(n=230)
Exemestane (n=247) p value fulvestrant plus 
anastrozole vs 
fulvestrant plus placebo
p value fulvestrant 
plus placebo vs 
exemestane
Any grade Grades 3 and 4 Any grade Grades 3 and 4 Any grade Grades 3 and 4
(Continued from previous page)
Rash 6 (2%) 0 4 (2%) 0 9 (4%) 0 0·75 0·26
Sciatica 4 (2%) 1 (<1%) 2 (1%) 0 1 (<1%) 0 0·69 0·61
Sinusitis 0 0 0 0 3 (1%) 0 ·· 0·25
Swelling 1 (<1%) 0 1 (<1%) 0 4 (2%) 0 1·00 0·37
Tooth infection 0 0 3 (1%) 0 0 0 0·12 0·11
Urinary-tract infection 7 (3%) 0 14 (6%) 0 8 (3%) 2 (1%) 0·12 0·19
Vaginal haemorrhage 4 (2%) 0 2 (1%) 0 0 0 0·69 0·23
Blurred vision 0 0 1 (<1%) 0 3 (1%) 1 (<1%) 0·49 0·62
Vulvovaginal dryness 2 (1%) 0 7 (3%) 0 2 (1%) 0 0·10 0·10
Weight loss 2 (1%) 0 3 (1%) 0 5 (2%) 1 (<1%) 0·68 0·73
Adverse events measured with Common Toxicity Criteria (version 3.0). *Prespeciﬁ ed.
Table 2: Adverse events
Figure 5: Oestradiol concentration
Error bars show 95% CI. 
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potentially indicating a group of patients with 
endocrine-responsive disease. However, despite 
recruitment of only patients with acquired resistance, 
heterogeneity in large phase 3 studies inevitably yields 
a mixed population of patients with ER-positive 
advanced breast cancer in terms of true endocrine 
responsiveness, which makes identiﬁ cation of those 
who could derive beneﬁ t from combined maximum 
endocrine treatment challenging.
The eﬀ ect of fulvestrant (with or without concomitant 
oestrogen suppression) might not have been better than 
that of exemestane in our trial because of a suboptimum 
dose of fulvestrant. Fulvestrant has a dose–response eﬀ ect 
on both ER downregulation and cell proliferation (as 
assessed by the proliferation marker Ki-67).17 Since SoFEA 
was initiated, two studies have suggested that fulvestrant’s 
eﬃ  cacy is increased at the monthly 500 mg intramuscular 
dose: the phase 2 FIRST study18 and subsequently in the 
larger phase 3 randomised CONFIRM study.19 The 
monthly 500 mg intramuscular dose of fulvestrant, with a 
loading dose schedule, was approved in 2010.
The blood samples we analysed provide evidence to 
suggest that relapse on NSAIs is not associated with 
loss of oestrogen suppression. Instead, intracellular 
signalling mechanisms for acquired resistance to these 
treatments probably exist because of either growth 
factor crosstalk or activation of other key regulatory and 
survival pathways.7 Targeting of signalling pathways at 
time of endocrine resistance has been shown to be 
eﬀ ective by the size of PFS improvement in BOLERO-2 
in this setting:8 median PFS was 10·6 months in 
patients assigned to exemestane and everolimus and 
4·1 months in those assigned to exemestane alone 
(HR 0·36, 95% CI 0·27–0·47; p<0·001). Notably, the 
populations studied in SoFEA and BOLERO-2 were 
similar in terms of age, previous use of adjuvant 
endocrine treatment, and, importantly, previous 
endocrine sensitivity. Additionally, eﬃ  cacy results for 
the control group who received exemestane were similar 
in the two trials. However, in the ﬁ rst-line endocrine-
sensitive setting, the combination of the mTOR 
antagonist temsirolimus with letrozole was no better 
than letrozole alone in the HORIZON trial,20 suggesting 
that optimum endocrine treatment alone still has a role 
in the endocrine-naive or hormone-sensitive setting.
In conclusion, our results conﬁ rm that the use of an 
ER downregulator in the presence of potent oestrogen 
deprivation provides no advantage for women with 
hormone-receptor-positive breast cancer who have 
progressed on previous treatment with a NSAI. 
Alternative strategies of combined endocrine therapy 
with signalling inhibitors should be explored to overcome 
endocrine resistance to NSAIs.
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Panel: Research in context
Systematic review
A comprehensive search for all available data and continuing 
trials reported in English was done in November, 2002. The 
search conﬁ rmed that no randomised trials of fulvestrant 
after treatment with non-steroidal aromatase inhibitors 
(NSAIs) in advanced breast cancer had been reported at the 
time this study was developed; therefore, no formal 
systematic review could be done. The best possible endocrine 
treatment in the group of patients identiﬁ ed for SoFEA was 
unclear, and evidence suggested that, despite acquired 
endocrine resistance, patients might derive clinical beneﬁ t 
from further endocrine treatment.1 Furthermore, preclinical 
studies9–12 suggested that fulvestrant could have improved 
eﬃ  cacy in a low-oestrogen environment, providing a clear 
rationale for exploration of maximum endocrine treatment 
in the setting of resistance to NSAI.
Interpretation
Investigation of fulvestrant in the setting of acquired resistance 
to NSAIs is unique to SoFEA, which thus supplements the 
results of the EFECT trial of fulvestrant versus exemestane.6 
SoFEA has provided evidence that after progression on NSAI, 
endocrine treatment options, such as exemestane or 
fulvestrant (with or without continued oestrogen suppression), 
give a median progression-free survival of only 3–4 months. 
However, the role of maximum dual endocrine treatment 
combining fulvestrant at the now approved increased dosing 
schedule and an aromatase inhibitor remains to be examined in 
true ﬁ rst-line endocrine-sensitive advanced breast cancer. 
Articles
998 www.thelancet.com/oncology   Vol 14   September 2013
References
1 Johnston SRD. Endocrine therapy for advanced breast cancer. In: 
Swanton C, Johnston SRD, eds. Handbook of metastatic breast 
cancer, 2nd edn. New York: Informa Healthcare, 2011: 13–34.
2 Lonning PE, Bajetta E, Murray R, et al. Activity of exemestane in 
metastatic breast cancer after failure of nonsteroidal aromatase 
inhibitors: a phase II trial. J Clin Oncol 2000; 18: 2234–44.
3 Bertelli G, Garrone O, Merlano M, et al. Sequential treatment with 
exemestane and non-steroidal aromatase inhibitors in advanced 
breast cancer. Oncology 2005; 69: 471–77.
4 Perey L. Fulvestrant (faslodex) as hormonal treatment in 
postmenopausal patients with advanced breast cancer progressing 
after treatment with tamoxifen and aromatase inhibitors—update of 
a phase II SAKK trial. Breast Cancer Res Treat 2004; 88 (suppl 1): 236.
5 Steger GG, Bartsch R, Wenzel C, et al. Fulvestrant (‘Faslodex’) in 
pre-treated patients with advanced breast cancer: a single-centre 
experience. Eur J Cancer 2005; 41: 2655–61.
6 Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized 
placebo controlled trial of fulvestrant compared with exemestane 
after prior non-steroidal aromatase inhibitor therapy in 
postmenopausal women with hormone receptor-positive, advanced 
breast cancer: results from EFECT. J Clin Oncol 2008; 26: 1664–70.
7 Johnston SRD. New strategies in estrogen receptor positive breast 
cancer. Clin Cancer Res 2010; 16: 1979–87.
8 Baselga J, Campone M, Piccart M, et al. Everolimus in 
postmenopausal hormone-receptor-positive advanced breast cancer. 
N Engl J Med 2012; 366: 520–29.
9 Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. 
Comparison of eﬀ ects of a pure steroidal antiestrogen with those of 
tamoxifen in a model of human breast cancer. J Natl Cancer Inst 
1995; 87: 746–50.
10 Martin LA, Pancholi S, Farmer I, Chan CMW, Dowsett M, 
Johnston SRD. The anti-estrogen ICI 182,780, but not tamoxifen, 
inhibits the growth of MCF-7 breast cancer cells refractory to 
long-term estrogen deprivation (LTED) through down-regulation 
of ER and IGF signalling. Endocr Relat Cancer 2005; 12: 1017–36.
11 Macedo LF, Sabnis GJ, Goloubeva OG, Brodie A. Combination of 
anastrozole with fulvestrant in the intratumoral aromatase 
xenograft model. Cancer Res 2008; 68: 3516–22.
12 Brodie A, Jelovac D, Macedo L, Sabnis G, Tilghman S, Goloubeva O. 
Therapeutic observations in MCF-7 aromatase xenografts. 
Clin Cancer Res 2005; 11: s884–88.
13 Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M. 
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal 
transduction pathways operate during the adaptation of MCF-7 cells 
to long term estrogen deprivation. J Biol Chem 2003; 278: 30458–68.
14 Shim WS, Conaway M, Masamura S, et al. Estradiol hypersensitivity 
and mitogen-activated protein kinase expression in long-term 
estrogen deprived human breast cancer cells in vivo. Endocrinology 
2000; 141: 396–405.
15 Bergh J, Jonsson PE, Lidbrink EK, et al. FACT: an open-label 
randomized phase III study of fulvestrant and anastrozole in 
combination compared with anastrozole alone as ﬁ rst-line therapy 
for patients with receptor-positive postmenopausal breast cancer. 
J Clin Oncol 2012; 30: 1919–25.
16 Mehta RS, Barlow WE, Albain KS, et al. Combination anastrozole 
and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 
367: 435–44.
17 Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the 
short-term biological eﬀ ects of 7alpha-[9-(4,4,5,5,5-
pentaﬂ uoropentylsulﬁ nyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol 
(Faslodex) versus tamoxifen in postmenopausal women with 
primary breast cancer. Cancer Res 2001; 61: 6739–46.
18 Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of 
fulvestrant 500 mg versus anastrozole 1 mg as ﬁ rst-line treatment 
for advanced breast cancer: results from the FIRST study. 
J Clin Oncol 2009; 27: 4530–35.
19 Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM 
phase III trial comparing fulvestrant 250 mg with fulvestrant 
500 mg in postmenopausal women with estrogen receptor-positive 
advanced breast cancer. J Clin Oncol 2010; 28: 4594–600.
20 Wolﬀ  AC, Lazar AA, Bondarenko I, et al. Randomized phase III 
placebo-controlled trial of letrozole plus oral temsirolimus as 
ﬁ rst-line endocrine therapy in postmenopausal women with locally 
advanced or metastatic breast cancer. J Clin Oncol 2013; 31: 195–202.
